Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Short-chain fatty acids (SCFAs), mainly including acetate, propionate, and butyrate, are
metabolites produced during the bacterial fermentation of dietary fiber in the intestinal tract …

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

The key objectives of medicinal chemistry are to efficiently design and synthesize bioactive
compounds that have the potential to become safe and efficacious drugs. Most medicinal …

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …

Molecular docking is a process through which small molecules are docked into the
macromolecular structures for scoring its complementary values at the binding sites. It is a …

After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has
become mainstream. More than 30 drug candidates derived from fragments have entered …

Cryo-electron microscopy (cryo-EM) of non-crystalline single particles is a biophysical
technique that can be used to determine the structure of biological macromolecules and …

Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-
molecule compounds starting from fragments binding weakly to targets. As FBDD exhibits …